Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market

FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet